Residual platelet reactivity: Predicting short-and long-term clinical outcome in patients undergoing percutaneous coronary revascularization

Biomarkers in Medicine

Volumn 4, Issue 3, 2010, Pages 421-434

  Mangiacapra, Fabio ^a   Barbato, Emanuele ^a  

^a OLV HOSPITAL   (Belgium)

Author keywords

Aspirin; Clopidogrel; Percutaneous coronary intervention; Platelet; Platelet function test

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ATORVASTATIN; CLOPIDOGREL; CYCLOOXYGENASE 1; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; OMEPRAZOLE; PRASUGREL; PROTON PUMP INHIBITOR; PURINERGIC P2Y12 RECEPTOR; THIENOPYRIDINE DERIVATIVE; TICAGRELOR;

ACUTE HEART INFARCTION; ANALYZER; ANTICOAGULATION; BLEEDING; BODY MASS; CLINICAL PRACTICE; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY STENT; DEVICE; DIABETES MELLITUS; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG ELUTING STENT; DRUG POTENCY; DRUG TARGETING; FLOW CYTOMETRY; FOLLOW UP; GENE MUTATION; GENETIC POLYMORPHISM; GOLD STANDARD; HEART DEATH; HEART MUSCLE REVASCULARIZATION; HUMAN; LIGHT TRANSMITTANCE AGGREGOMETRY; LOADING DRUG DOSE; PATIENT MONITORING; PERCUTANEOUS CORONARY INTERVENTION; POINT OF CARE TESTING; PRACTICE GUIDELINE; PREDICTION; PROTEIN PHOSPHORYLATION; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STROKE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; THROMBOELASTOGRAPHY; THROMBOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSTABLE ANGINA PECTORIS; WHOLE BLOOD AGGREGOMETRY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ASPIRIN; BLOOD PLATELETS; HUMANS; MYOCARDIAL ISCHEMIA; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PREDICTIVE VALUE OF TESTS; RECURRENCE; TICLOPIDINE;

EID: 77953730351     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/bmm.10.56     Document Type: Review

References (109)

1. Davi G, Patrono C: Platelet activation and atherothrombosis. N. Engl. J. Med. 357, 2482-2494 (2007).
2. Wilentz JR, Sanborn TA, Haudenschild CC, Valeri CR, Ryan TJ, Faxon DP: Platelet accumulation in experimental angioplasty: time course and relation to vascular injury. Circulation 75, 636-642 (1987).
3. Mehta SR, Yusuf S, Peters RJ et al.: Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358, 527-533 (2001).
4. Steinhubl SR, Berger PB, Mann JT 3rd et al.: Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288, 2411-2420 (2002).
5. Wiviott SD, Braunwald E, McCabe CH et al.: Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357, 2001-2015 (2007). (Pubitemid 350106708)
6. Wallentin L, Becker RC, Budaj A et al.: Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361, 1045-1057 (2009).
7. Cuisset T, Cayla G, Frere C et al.: Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment? EuroIntervention 5, 325-329 (2009).
8. Kleiman NS, Grazeiadei N, Maresh K et al.: Abciximab, ticlopidine, and concomitant abciximab-ticlopidine therapy: ex vivo platelet aggregation inhibition profiles in patients undergoing percutaneous coronary interventions. Am. Heart J. 140, 492-501 (2000).
9. Dalby M, Montalescot G, Bal dit Sollier C et al.: Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel. Results of the Platelet Activity Extinction in Non-Q-wave Myocardial Infarction with Aspirin, Clopidogrel, and Eptifibatide (PEACE) study. J. Am. Coll. Cardiol. 43, 162-168 (2004).
10. Gurbel PA, Bliden KP, Zaman KA, Yoho JA, Hayes KM, Tantry US: Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation 111, 1153-1159 (2005).
11. Patrono C: Aspirin as an antiplatelet drug. N. Engl. J. Med. 330, 1287-1294 (1994).
12. Bradlow BA, Chetty N: Dosage frequency for suppression of platelet function by low dose aspirin therapy. Thromb. Res. 27, 99-110 (1982).
13. Awtry EH, Loscalzo J: Aspirin. Circulation. 101, 1206-1218 (2000).
14. Altman R, Luciardi HL, Muntaner J, Herrera RN: The antithrombotic profile of aspirin. Aspirin resistance, or simply failure? Thromb. J. 2(1), 1 (2004).
15. Husain S, Andrews NP, Mulcahy D, Panza JA, Quyyumi AA: Aspirin improves endothelial dysfunction in atherosclerosis. Circulation. 97, 716-720 (1998).
16. Steer KA, Wallace TM, Bolton CH, Hartog M: Aspirin protects low density lipoprotein from oxidative modification. Heart 77, 333-337 (1997).
17. Antithrombotic Trialists' Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324, 71-86 (2002).
18. Baigent C, Blackwell L, Collins R et al.: Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373, 1849-1860 (2009).
19. Sanderson S, Emery J, Baglin T, Kinmonth AL: Narrative review: aspirin resistance and its clinical implications. Ann. Intern. Med. 142, 370-380 (2005).
20. Grove EL, Hvas AM, Johnsen HL et al.: A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease. Thromb. Haemost. (2010) (Epub ahead of print).
21. Schwartz KA, Schwartz DE, Ghosheh K, Reeves MJ, Barber K, DeFranco A: Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am. J. Cardiol. 95, 973-975 (2005).
22. Cuisset T, Frere C, Quilici J et al.: Aspirin noncompliance is the major cause of "aspirin resistance" in patients undergoing coronary stenting. Am. Heart J. 157, 889-893 (2009).
23. ten Berg JM, Gerritsen WB, Haas FJ, Kelder HC, Verheugt FW, Plokker HW: High-dose aspirin in addition to daily low-dose aspirin decreases platelet activation in patients before and after percutaneous coronary intervention. Thromb. Res. 105, 385-390 (2002).
24. Lincoff AM, Popma JJ, Ellis SG, Hacker JA, Topol EJ: Abrupt vessel closure complicating coronary angioplasty: clinical, angiographic and therapeutic profile. J. Am. Coll. Cardiol. 19, 926-935 (1992).
25. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N. Engl. J. Med. 330(14), 956-961 (1994).
26. Peltonen S, Lassila R, Heikkila J: Activation of coagulation and fibrinolysis despite heparinization during successful elective coronary angioplasty. Thromb. Res. 82, 459-468 (1996).
27. Gregorini L, Marco J, Fajadet J et al.: Ticlopidine and aspirin pretreatment reduces coagulation and platelet activation during coronary dilation procedures. J. Am. Coll. Cardiol. 29, 13-20 (1997).
28. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH: Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 102, 624-629 (2000).
29. Kushner FG, Hand M, Smith SCJ et al.: 2009 Focused Updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 120, 2271-2306 (2009).
30. Quinn MJ, Fitzgerald DJ: Ticlopidine and clopidogrel. Circulation 100, 1667-1672 (1999).
31. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al.: Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J. Am. Coll. Cardiol. 49, 1505-1516 (2007).
32. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al.: Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler. Thromb. Vasc. Biol. 26, 1895-1900 (2006).
33. Hulot JS, Bura A, Villard E et al.: Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108, 2244-2247 (2006).
34. Mega JL, Close SL, Wiviott SD et al.: Cytochrome P-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 360, 354-362 (2009).
35. Collet JP, Hulot JS, Pena A et al.: Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 373, 309-317 (2009).
36. Gladding P, Webster M, Zeng I et al.: The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial. JACC Cardiovasc. Interv. 1, 620-627 (2008).
37. Gladding P, White H, Voss J et al.: Pharmacogenetic testing for clopidogrel using the rapid INFINITI analyzer: a dose-escalation study. JACC Cardiovasc. Interv. 2, 1095-1101 (2009).
38. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al.: Platelet function profiles in patients with Type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 54, 2430-2435 (2005).
39. Angiolillo DJ, Bernardo E, Ramirez C et al.: Insulin therapy is associated with platelet dysfunction in patients with Type 2 diabetes mellitus on dual oral antiplatelet treatment. J. Am. Coll. Cardiol. 48, 298-304 (2006).
40. Sibbing D, von Beckerath O, Schomig A, Kastrati A, von Beckerath N: Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of clopidogrel before percutaneous coronary intervention. Am. J. Cardiol. 100, 203-205 (2007).
41. Sibbing D, von Beckerath O, Schomig A, Kastrati A, von Beckerath N: Platelet function in clopidogrel-treated patients with acute coronary syndrome. Blood Coagul. Fibrinolysis 18, 335-339 (2007).
42. Muller O, Hamilos M, Bartunek J et al.: Relation of endothelial function to residual platelet reactivity after clopidogrel in patients with stable angina pectoris undergoing percutaneous coronary intervention. Am. J. Cardiol. 105, 333-338 (2010).
43. Mangiacapra F, De Bruyne B, Muller O et al.: High residual platelet reactivity after clopidogrel extent of coronary atherosclerosis and periprocedural myocardial infarction in patients with stable angina undergoing percutaneous coronary intervention. JACC Cardiovasc. Interv. 3, 35-40 (2010).
44. Lau WC, Waskell LA, Watkins PB et al.: Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 107, 32-37 (2003).
45. Muller I, Besta F, Schulz C, Li Z, Massberg S, Gawaz M: Effects of statins on platelet inhibition by a high loading dose of clopidogrel. Circulation 108, 2195-2197 (2003).
46. Mitsios JV, Papathanasiou AI, Rodis FI, Elisaf M, Goudevenos JA, Tselepis AD: Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation 109, 1335-1338 (2004).
47. Gilard M, Arnaud B, Cornily JC et al.: Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole Clopidogrel Aspirin) study. J. Am. Coll. Cardiol. 51, 256-260 (2008).
48. Sibbing D, Morath T, Stegherr J et al.: Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb. Haemost. 101, 714-719 (2009).
49. Cuisset T, Frere C, Quilici J et al.: Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study. J. Am. Coll. Cardiol. 54, 1149-1153 (2009).
50. O'Donoghue ML, Braunwald E, Antman EM et al.: Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 374, 989-997 (2009).
51. Cadroy Y, Bossavy JP, Thalamas C, Sagnard L, Sakariassen K, Boneu B: Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans. Circulation 101, 2823-2828 (2000).
52. Sabatine MS, Cannon CP, Gibson CM et al.: Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 294, 1224-1232 (2005).
53. Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, Di Sciascio G: Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of Myocardial Damage during Angioplasty) study. Circulation 111, 2099-2106 (2005).
54. Mehta SR, Bassand JP, Chrolavicius S et al.: Design and rationale of CURRENT-OASIS 7: a randomized, 2 × 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. Am. Heart J. 156, 1080-1088.e1 (2008).
55. von Beckerath N, Taubert D, Pogatsa-Murray G, Schomig E, Kastrati A, Schomig A: Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) trial. Circulation 112, 2946-2950 (2005).
56. Montalescot G, Sideris G, Meuleman C et al.: A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J. Am. Coll. Cardiol. 48, 931-938 (2006).
57. Michelson AD: Methods for the measurement of platelet function. Am. J. Cardiol. 103, 20A-26A (2009).
58. Born GV: Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 194, 927-929 (1962).
59. Cardinal DC, Flower RJ: The electronic aggregometer: a novel device for assessing platelet behavior in blood. J. Pharmacol. Methods 3, 135-158 (1980).
60. Steinhubl SR: The VerifyNow system. In: Platelets (2nd Edition). Michelson AD (Ed.). Elsevier/Academic Press, CA, USA 509-518 (2007).
61. Golanski J, Pluta J, Baraniak J, Watala C: Limited usefulness of the PFA-100 for the monitoring of ADP receptor antagonists - in vitro experience. Clin. Chem. Lab. Med. 42, 25-29 (2004).
62. Schwarz UR, Geiger J, Walter U, Eigenthaler M: Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets - definition and detection of ticlopidine/clopidogrel effects. Thromb. Haemost. 82, 1145-1152 (1999).
63. Hartert H: Thrombelastography, a method for physical analysis of blood coagulation. Z. Gesamte Exp. Med. 117, 189-203 (1951).
64. Sofi F, Marcucci R, Gori AM, Abbate R, Gensini GF: Residual platelet reactivity on aspirin therapy and recurrent cardiovascular events - a meta-analysis. Int J Cardiol. 128, 166-171 (2008).
65. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR: Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 336, 195-198 (2008).
66. Gurbel PA, Bliden KP, DiChiara J et al.: Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin- Induced Platelet Effect (ASPECT) study. Circulation 115, 3156-3164 (2007).
67. Michelson AD, Cattaneo M, Eikelboom JW et al.: Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J. Thromb. Haemost. 3, 1309-1311 (2005).
68. Chen WH, Lee PY, Ng W, Tse HF, Lau CP: Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J. Am. Coll. Cardiol. 43, 1122-1126 (2004).
69. Lev EI, Patel RT, Maresh KJ et al.: Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J. Am. Coll. Cardiol. 47, 27-33 (2006).
70. Cuisset T, Frere C, Quilici J et al.: High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J. Thromb. Haemost. 4, 542-549 (2006).
71. Gori AM, Marcucci R, Migliorini A et al.: Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents. J. Am. Coll. Cardiol. 52, 734-739 (2008).
72. Gianetti J, Parri MS, Sbrana S et al.: Platelet activation predicts recurrent ischemic events after percutaneous coronary angioplasty: a 6 months prospective study. Thromb. Res. 118, 487-493 (2006).
73. Marcucci R, Paniccia R, Antonucci E et al.: Usefulness of aspirin resistance after percutaneous coronary intervention for acute myocardial infarction in predicting one-year major adverse coronary events. Am. J. Cardiol. 98, 1156-1159 (2006).
74. Tantry US, Bliden KP, Gurbel PA: Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J. Am. Coll. Cardiol. 46, 1705-1709 (2005).
75. Matetzky S, Shenkman B, Guetta V et al.: Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109, 3171-3175 (2004).
76. Marcucci R, Gori AM, Paniccia R et al.: Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 119, 237-242 (2009).
77. Cuisset T, Frere C, Quilici J et al.: High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes. Thromb. Haemost. 97, 282-287 (2007).
78. Cuisset T, Frere C, Quilici J et al.: Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J. Am. Coll. Cardiol. 48, 1339-1345 (2006).
79. Frere C, Cuisset T, Quilici J et al.: ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thromb. Haemost. 98, 838-843 (2007).
80. Gurbel PA, Bliden KP, Saucedo JF et al.: Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic indexes, and their relation to periprocedural infarction results of the CLEAR PLATELETS-2 (Clopidogrel with Eptifibatide to Arrest the Reactivity of Platelets) study. J. Am. Coll. Cardiol. 53, 648-657 (2009).
81. Gurbel PA, Bliden KP, Guyer K et al.: Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J. Am. Coll. Cardiol. 46, 1820-1826 (2005).
82. Hochholzer W, Trenk D, Bestehorn HP et al.: Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J. Am. Coll. Cardiol. 48, 1742-1750 (2006).
83. Geisler T, Langer H, Wydymus M et al.: Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur. Heart J. 27, 2420-2425 (2006).
84. Bliden KP, DiChiara J, Tantry US, Bassi AK, Chaganti SK, Gurbel PA: Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? J. Am. Coll. Cardiol. 49, 657-666 (2007).
85. Gurbel PA, Antonino MJ, Bliden KP et al.: Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target. Platelets 19, 595-604 (2008).
86. Wang ZJ, Zhou YJ, Liu YY et al.: Impact of clopidogrel resistance on thrombotic events after percutaneous coronary intervention with drug-eluting stent. Thromb. Res. 124, 46-51 (2009).
87. Bonello L, Paganelli F, Arpin-Bornet M et al.: Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J. Thromb. Haemost. 5, 1630-1636 (2007).
88. Cuisset T, Hamilos M, Sarma J et al.: Relation of low response to clopidogrel assessed with point-of-care assay to periprocedural myonecrosis in patients undergoing elective coronary stenting for stable angina pectoris. Am. J. Cardiol. 101, 1700-1703 (2008).
89. Patti G, Nusca A, Mangiacapra F, Gatto L, D'Ambrosio A, Di Sciascio G: Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of Myocardial Damage during Angioplasty- Platelet Reactivity Predicts Outcome) study. J. Am. Coll. Cardiol. 52, 1128-1133 (2008).
90. Buonamici P, Marcucci R, Migliorini A et al.: Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J. Am. Coll. Cardiol. 49, 2312-2317 (2007).
91. Gurbel PA, Bliden KP, Samara W et al.: Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST study. J. Am. Coll. Cardiol. 46, 1827-1832 (2005).
92. Sibbing D, Braun S, Morath T et al.: Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J. Am. Coll. Cardiol. 53, 849-856 (2009).
93. Mangiacapra F, Barbato E, Patti G et al.: Point-of-care assessment of platelet reactivity after clopidogrel to predict myonecrosis in patients undergoing percutaneous coronary intervention. JACC Cardiovasc. Interv. 3, 318-323 (2010).
94. Buch AN, Singh S, Roy P et al.: Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention. Am. J. Cardiol. 99, 1518-1522 (2007).
95. Price MJ, Endemann S, Gollapudi RR et al.: Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur. Heart J. 29, 992-1000 (2008).
96. Breet NJ, van Werkum JW, Bouman HJ et al.: Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 303, 754-762 (2010).
97. Bonello L, Camoin-Jau L, Arques S et al.: Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J. Am. Coll. Cardiol. 51, 1404-1411 (2008).
98. Aleil B, Jacquemin L, De Poli F et al.: Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator- Stimulated Phosphoprotein-02) randomized study. JACC Cardiovasc. Interv. 1, 631-638 (2008).
99. Cuisset T, Frere C, Quilici J et al.: Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study. JACC Cardiovasc. Interv. 1, 649-653 (2008).
100. Valgimigli M, Campo G, de Cesare N et al.: Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study. Circulation 119, 3215-3222 (2009).
101. Wiviott SD, Trenk D, Frelinger AL et al.: Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 116, 2923-2932 (2007).
102. Wallentin L, Varenhorst C, James S et al.: Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur. Heart J. 29, 21-30 (2008).
103. Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G: Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur. Heart J. 27, 1038-1047 (2006).
104. Cannon CP, Harrington RA, James S et al.: Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet 375(9711), 283-293 (2010).
105. Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel (TRIGGER-PCI) trial http://clinicaltrials.gov/ct2/show/NCT00910 299?term=NCT00910299&rank=1
106. Double Randomization of a Monitoring Adjusted Antiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation, and Interruption Versus Continuation of Double Antiplatelet Therapy (ARCTIC) trial http://clinicaltrials.gov/ct2/show/NCT00827 411?term=NCT00827411&rank=1
107. Assessment of Dual Antiplatelet Therapy With Drug Eluting Stents (ADAPT-DES) trial http://clinicaltrials.gov/ct2/show/NCT00638 794?term=NCT00638794&rank=1
108. Gauging Responsiveness With A VerifyNow Assay-Impact On Thrombosis And Safety (GRAVITAS) trial http://clinicaltrials.gov/ct2/show/ NCT00645918?term= NCT00645918 &rank=1
109. Dual Antiplatelet Therapy Tailored on the Extent of Platelet Inhibition (DANTE) trial http://clinicaltrials.gov/ct2/show/ NCT00774475?term=NCT00774475 &rank=1